A SPARK-BIH funded project on the development of an innovative tumor-specific immunotherapy for the treatment of B-cell lymphomas has successfully been awarded a follow-on BMBF grant for a first-in-human clinical trial.
Dr. Angelika Vlachou, Principal at High-Tech Gründerfonds (HTGF), supported 25 translational SPARK project teams with a dedicated hands-on Pitch Training Workshop.
After the successful implementation of the NeuroCure/SPARK program, NeuroCure and SPARK-BIH prolong their collaboration and will run a second call for projects.
Researchers led by our SPARKee Ulrike Stein of the ECRC and Robert Preißner of Charité report in "Clinical and Translational Medicine" that statins inhibit a gene that promotes cancer cell metastasis.
The Charité Spin-off BODYCLOCK Technologies by Prof. Dr. Achim Kramer developed a diagnostic assay to assess the circadian clock. The project has previously been supported by SPARK-BIH and BIH Digital Health Accelerator.